Personalized treatment of RET-altered thyroid cancers episode artwork

EPISODE · Mar 16, 2022 · 42 MIN

Personalized treatment of RET-altered thyroid cancers

from touchPODCAST · host touchpodcast

touchEXPERT OPINIONS for touchENDOCRINOLOGY Listen to leading experts explain the value of biomarker testing and targeted therapies for the personalized treatment of RET-altered thyroid cancers The experts Prof. Maria Cabanillas - University of Texas MD Anderson Cancer Center, Houston, TX, USA Dr Vivek Subbiah - University of Texas MD Anderson Cancer Center, Houston, TX, USA Dr Lori Wirth - Center for Head and Neck Cancers, Massachusetts General Hospital, Boston, MA, USA This touchPODCAST is for HCPs only. This activity is funded by an unrestricted independent medical educational grant from Blueprint Medicines and Genentech, a member of the Roche Group. This activity is jointly provided by USF Health and touchIME. For further information visit our website: https://touchendocrinologyime.org/personalized-treatment-of-ret-altered-thyroid-cancers-what-is-the-value-of-biomarker-testing-and-targeted-therapies//?_ga=2.65262702.1175448380.1654530922-407959475.1653925964

Episode metadata supplied by the publisher feed · Published Mar 16, 2022

Embed this episode

Ready to play

Personalized treatment of RET-altered thyroid cancers

0:00 42:42

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

No similar episodes found.

No similar podcasts found.

Frequently Asked Questions

How long is this episode of touchPODCAST?

This episode is 42 minutes long.

When was this touchPODCAST episode published?

This episode was published on March 16, 2022.

Can I download this touchPODCAST episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!